Work

Overall survival (OS) and duration of response for transfusion independence (TI) in erythropoiesis stimulating agent (ESA)–naive patients (pts) with very low-, low-, or intermediate-risk myelodysplastic syndromes (MDS) treated with luspatercept (LUSPA) vs epoetin alfa (EA) in the COMMANDS trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.6512

Authors: Guillermo Garcia-Manero, Matteo Giovanni Della Porta, Amer Methqal Zeidan, Rami S. Komrokji, Veronika Pozharskaya, Shelonitda Rose, Karen Keeperman, Yinzhi Lai, Sameer Kalsekar, Barkha Aggarwal, Dimana Miteva, David Valcárcel, Pierre Fenaux, Jake Shortt, Uwe Platzbecker, Valeria Santini

Institutions: The University of Texas MD Anderson Cancer Center, IRCCS Humanitas Research Hospital, Yale University, Moffitt Cancer Center, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (India), Bristol-Myers Squibb (Switzerland), Vall d'Hebron Hospital Universitari, Université Paris Cité, Hôpital Saint-Louis, Monash Health, Monash University, University Hospital Leipzig, Azienda Ospedaliero-Universitaria Careggi, University of Florence

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410809620

Cites:

Cited by: 5

Related to: 10